Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy
|ClinicalTrials.gov Identifier: NCT00450567|
Recruitment Status : Completed
First Posted : March 22, 2007
Last Update Posted : October 30, 2015
RATIONALE: Measuring changes in glucose metabolism in patients with cancer may help doctors predict how patients respond to treatment.
PURPOSE: This clinical trial is studying glucose metabolism in patients with non-small cell lung cancer treated with targeted therapy and chemotherapy.
|Condition or disease||Intervention/treatment|
|Lung Cancer||Procedure: computed tomography Procedure: positron emission tomography Radiation: fludeoxyglucose F 18|
- Determine the prognostic significance of changes in glucose metabolism measured by fludeoxyglucose F 18 positron emission tomography (FDG-PET)/CT scan in patients with non-small cell lung cancer treated with targeted drugs comprising gefitinib, erlotinib hydrochloride, or other ErbB inhibitors, cyclooxygenase-2 inhibitors, or estrogen receptor blockers in combination with conventional chemotherapy.
OUTLINE: This is a prospective study.
Patients undergo fludeoxyglucose F 18 positron emission tomography (FDG-PET) scan and CT scan at baseline and at 2 weeks and 12 weeks after receiving targeted anticancer treatment. Metabolic changes detected by FDG-PET and size changes identified by CT scan are related to patient outcome and tumor response to treatment.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||36 participants|
|Official Title:||Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT|
|Study Start Date :||December 2004|
|Actual Primary Completion Date :||July 2012|
|Actual Study Completion Date :||July 2012|
- Correlation of glucose metabolic response with progression-free survival, overall survival, and changes in tumor size as measured by fludeoxyglucose F 18 positron emission tomography/CT scan [ Time Frame: 3 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00450567
|United States, California|
|Jonsson Comprehensive Cancer Center at UCLA|
|Los Angeles, California, United States, 90095-1781|
|Study Chair:||Johannes Czernin, MD||Jonsson Comprehensive Cancer Center|